These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 21354445

  • 1. Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
    Deltenre P, Corouge M, Canva V, Castel H, Wartel F, Dharancy S, Louvet A, Lazrek M, Moreno C, Henrion J, Mathurin P.
    J Hepatol; 2011 Nov; 55(5):989-95. PubMed ID: 21354445
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E.
    World J Gastroenterol; 2014 Nov 28; 20(44):16726-33. PubMed ID: 25469044
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.
    Klin Mikrobiol Infekc Lek; 2008 Apr 28; 14(2):67-73. PubMed ID: 18756436
    [Abstract] [Full Text] [Related]

  • 6. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.
    Bárcena R, Moreno A, del Campo S, Muriel A, Mateos ML, Garrido E, García M, Quereda C, Moreno S, Moreno A.
    Antivir Ther; 2007 Apr 28; 12(3):401-6. PubMed ID: 17591030
    [Abstract] [Full Text] [Related]

  • 7. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun 28; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M, Kakizaki S, Yata Y, Yamazaki Y, Horiguchi N, Sato K, Takagi H, Mori M.
    J Gastroenterol Hepatol; 2012 Jan 28; 27(1):69-75. PubMed ID: 21649727
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.
    J Womens Health (Larchmt); 2015 Feb 28; 24(2):159-64. PubMed ID: 25682817
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.
    New Microbiol; 2005 Jan 28; 28(1):13-21. PubMed ID: 15782622
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.